Literature DB >> 7992345

Towards optimal regimens of parenteral quinine for young African children with cerebral malaria: unbound quinine concentrations following a simple loading dose regimen.

P A Winstanley1, E K Mberu, W M Watkins, S A Murphy, B Lowe, K Marsh.   

Abstract

Nine children with severe falciparum malaria were treated with an intravenous quinine regimen which did not require burettes or infusion pumps, to determine its practicability and to ensure that therapeutic drug concentrations were achieved and maintained throughout the dose interval. The regimen comprised quinine dihydrochloride (15 mg/kg; 12.5 mg/kg of the free base), which was added to a bag of intravenous fluid (after wastage of all but 100 mL), and given via standard giving sets over 2 h. Blood was drawn sequentially during the infusion, and for 12 h thereafter; plasma water was obtained by ultrafiltration of samples at the bedside, and quinine concentration was measured, in plasma and plasma water, by high performance liquid chromatography. Drug administration was practicable without burettes or infusion pumps; unbound drug concentrations exceeded the 99% inhibitory concentration for local parasites within 0.5 h, and remained within the therapeutic range for the entire dose interval. This loading dose regimen can now be recommended for young children in African hospitals; maintenance doses of 10 mg/kg should be given at 12 h intervals until oral antimalarial drugs are possible. These recommendations will need to be modified if susceptibility to quinine declines.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7992345     DOI: 10.1016/0035-9203(94)90170-8

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  11 in total

Review 1.  Cerebral malaria.

Authors:  C R Newton; T T Hien; N White
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-10       Impact factor: 10.154

Review 2.  Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.

Authors:  S Krishna; N J White
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

Review 3.  Cerebral malaria: optimising management.

Authors:  Neema Mturi; Crispin O Musumba; Betty M Wamola; Bernhards R Ogutu; Charles R J C Newton
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 4.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 5.  High first dose quinine regimen for treating severe malaria.

Authors:  A Lesi; M Meremikwu
Journal:  Cochrane Database Syst Rev       Date:  2004

6.  Pharmacokinetics and clinical efficacy of lorazepam in children with severe malaria and convulsions.

Authors:  Simon N Muchohi; Kenneth Obiero; Charles R J C Newton; Bernhards R Ogutu; Geoffrey Edwards; Gilbert O Kokwaro
Journal:  Br J Clin Pharmacol       Date:  2007-07-17       Impact factor: 4.335

7.  Hypoglycaemia in severe malaria, clinical associations and relationship to quinine dosage.

Authors:  Gilbert N Ogetii; Samuel Akech; Julie Jemutai; Mwanamvua Boga; Esther Kivaya; Greg Fegan; Kathryn Maitland
Journal:  BMC Infect Dis       Date:  2010-11-22       Impact factor: 3.090

Review 8.  Treatment of African children with severe malaria - towards evidence-informed clinical practice using GRADE.

Authors:  Nyokabi Musila; Newton Opiyo; Mike English
Journal:  Malar J       Date:  2011-07-21       Impact factor: 2.979

9.  Pentoxifylline as an adjunct therapy in children with cerebral malaria.

Authors:  Bertrand Lell; Carsten Köhler; Betty Wamola; Christopher Ho Olola; Esther Kivaya; Gilbert Kokwaro; David Wypij; Sadik Mithwani; Terrie E Taylor; Peter G Kremsner; Charles R J C Newton
Journal:  Malar J       Date:  2010-12-21       Impact factor: 2.979

10.  Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions.

Authors:  Simon N Muchohi; Gilbert O Kokwaro; Bernhards R Ogutu; Geoffrey Edwards; Steve A Ward; Charles R J C Newton
Journal:  Br J Clin Pharmacol       Date:  2008-06-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.